RE:Merck's keytruda snags 5th approval in single cancer - NSCLCJanuary 27, 2023 - "Merck & Co.’s Keytruda has long been viewed as a standard of care in metastatic non-small cell lung cancer (NSCLC). Now, the PD-1 king has scored the FDA’s permission to enter early-stage disease with an approval that trumps Roche’s Tecentriq.
The FDA has cleared Keytruda for use after surgery and chemotherapy for early NSCLC across stages 1B, 2 or 3A, Merck said Friday. The approval covers patients regardless of their tumor’s PD-L1 expression levels."
PD-1/L1 inhibitors are known to work better in PD-L1-high cases, so the poor showing in that subgroup in KEYNOTE-091 came as a surprise.
[ ONCY's pelareorep is utilizing a biomarker to target PD-(L)1 low (cold) cancers, and thus is capable of turning cold cancers into "hot" cancers, by remodeling the TME, stimulating the innate and adaptive immune systems, and making the TME favorable for the addition immune checkpoint inhibitor therapy ]
https://www.fiercepharma.com/marketing/mercks-keytruda-rises-adjuvant-lung-cancer-broader-fda-approval-roches-tecentriq